Evidence map›Paper›PMID 38175731›Full record

ArticleJCI insight2024

Evolutionary mode and timing of dissemination of high-grade serous carcinomas.

Anita Sveen, Bjarne Johannessen, Solveig Mk Klokkerud, Sigrid M Kraggerud, Leonardo A Meza-Zepeda, Merete Bjørnslett, Katharina Bischof, Ola Myklebost, Kjetil Taskén, Rolf I Skotheim and 3 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Anita SveenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Bjarne JohannessenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Solveig Mk KlokkerudDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Sigrid M KraggerudDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Leonardo A Meza-ZepedaDepartment of Tumor Biology, Institute for Cancer Research.
Merete BjørnslettDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Katharina BischofDepartment of Gynecological Oncology, The Norwegian Radium Hospital, and.
Ola MyklebostDepartment of Tumor Biology, Institute for Cancer Research.
Kjetil TaskénInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Rolf I SkotheimDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Anne DørumDepartment of Gynecological Oncology, The Norwegian Radium Hospital, and.
Ben DavidsonInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Ragnhild A LotheDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary trajectories across a median of 5 tumor sites and regions from each of 23 patients based on deep whole-exome sequencing. Polyclonal cancer origin was detected in 1 patient. Ovarian tumors had more complex subclonal architectures than other intraperitoneal tumors in each patient, which indicated that tumors developed earlier in the ovaries. Three common modes of dissemination were identified, including monoclonal or polyclonal dissemination of monophyletic (linear) or polyphyletic (branched) subclones. Mutation profiles of initial or disseminated clones varied greatly among cancers, but recurrent mutations were found in 7 cancer-critical genes, including TP53, BRCA1, BRCA2, and DNMT3A, and in the PI3K/AKT1 pathway. Disseminated clones developed late in the evolutionary trajectory models of most cancers, in particular in cancers with DNA damage repair deficiency. Polyclonal dissemination was predicted to occur predominantly as a single and rapid wave, but chemotherapy exposure was associated with higher genomic diversity of disseminated clones. In conclusion, we described three common evolutionary dissemination modes across HGSCs and proposed factors associated with dissemination diversity.

Indexed as

CarcinomaOvarian NeoplasmsFemaleHumansMutationBioinformaticsClonal selectionGeneticsMolecular biologyOncology

Identifiers

PMID38175731
PMCPMC11143962
OpenAlexW4390589275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.